CELG - An In-Depth Look At Jounce Therapeutics
Nothing strengthens authority so much as silence." - Leonardo da Vinci
Today, we look at a small, early-stage development firm trying to use the body's immune system to attack tumors.
Company Overview:
Jounce Therapeutics (JNCE) IPO'd in 2017 and is a Massachusetts-based clinical-stage biotechnology company focused on developing therapeutics aimed at treating cancer by mobilizing one's immune system to attack tumors. The company's development strategy is to target a specific mechanism that matches the composition of the immune system within the patient's tumor microenvironment. The company's pipeline is comprised of early-stage assets